Rebirth of the God-level Xueba

When Arnold returned to the company, he summoned the company's scientific research apes, and then described in detail what he saw in the Huarui laboratory. Although he omitted the part that cannot be said in the confidentiality agreement, his description is enough for researchers We refer to it.

In fact, the non-disclosure agreement was originally for Yang Rui to prevent problems before they happen. In his laboratory, there are no mysterious materials that can be taken away.

Arnold finished his description, and then asked: "Do you think there is hope? Yang Rui's deferiprone project."

After several researchers discussed in a low voice, the new Chief Technology Officer Van Lundin said: "Based on the conditions known so far, deferiprone has been synthesized, so there is no problem with the active substance. As long as it is made active substances, it is necessary to continue to do so.”

Van Lundin is here to replace Trapp. As a well-known expert in biology and chemistry, the latter is just starting up in China and came to help.

Compared with the professor at the University of Sheffield, Van Lundin's qualifications are slightly inferior. His most remarkable achievement is that he participated in the Olympic Games as a rowing rower from Cambridge, and that's all.

Fan Lundin did not have much contact with Yang Rui, so he considered it purely from scientific research, and said: "I don't think it is a good idea to do drug research in China. Even if he wants to sell his company for a good price, it is not worth making original drugs." .If deferiprone takes the rare drug route, it can indeed save a lot of trouble, but it is still very troublesome and not an appropriate choice."

"He has already chosen. I think the crux of the question should be, do you think Yang Rui can succeed?" Arnold asked very seriously, and this is indeed a key question.

Van Lundin thought for a moment, but did not dare to categorically deny it, and said: "It's hard to judge, but you know, even if 100 active substances are synthesized, they may not pass animal tests, let alone human clinical trials. He is far from successful." It's still far away."

Other researchers also nodded, expressing their dislike for Yang Rui's research.

Zeneca's researcher in China is mainly responsible for solving the production problems of the coenzyme q10 factory, and at the same time helping Chinese partners to build new factories. He has also dealt with Yang Rui.

However, they used to regard Yang Rui as a figure in the academic circle, but now they saw him enter the industrial circle, and all of them revealed the inherent prejudice that people in the industrial circle have against academic circles.

"Developing original drugs is not so easy, and it is very difficult for Yang Rui to succeed."

"Unlikely to succeed."

"Maybe he wants to sell us the active substance?"

"It has to pass the animal experiment before it is worth selling."

After listening to their discussion, Arnold also changed his mind, and said: "As far as I know, Yang Rui's record is very good. He is now intervening in the production of deferiprone. I am afraid he has some cards."

Van Lundin smiled and said: "It's nothing unusual for every researcher to be confident that he will succeed before starting the experiment. As you can see, how many drugs can be successfully produced in the end? In our company, there are too many researchers with great records. Who can guarantee that their next new drug will be successful."

Arnold lowered his head in thought, suddenly made an expression of thinking of something, shook his head, and asked, "Van Lundin, I remember you did new drug development before?"

"right."

"What was the result?"

"The project failed, the company reorganized the project team,

Failed again, the company reorganized the team, continued to fail, and the company made additional investments, but still failed, and the project team was finally disbanded. "Van Lundin described the seven years that once belonged to him in the most succinct way.

Arnold seemed unaware, and asked, "What step have you achieved?"

"Clinical Phase II."

"From target screening, to drug synthesis, to animal experiments, and then clinical phase I, clinical phase II... all the way, it's a pity to give up at the final stage." Arnold doesn't know much about scientific research, but he has a good understanding of project management etc., are still well known.

"It's a pity, but the effectiveness test failed. If we continue, it will only cost more money." Van Lundin spoke from the company's standpoint with a blank expression.

Phase 1 of a clinical trial is the safety testing phase of a drug, usually in 20 to 40 healthy volunteers, and costs less than $1 million.

The second phase of clinical trials is the stage of drug effectiveness testing, which requires 100 to 300 patients, and the cost usually exceeds 20 million US dollars.

As for the third phase of clinical trials, it is the stage of large-scale verification of the safety and effectiveness of drugs. Since it is large-scale, there must be a large number of people. In the testing of non-rare drugs, the number of people in the third phase of clinical trials will usually increase. To 20,000 people, the cost has also reached a staggering $100 million or more.

It is conceivable that no company will rush to advance the progress of clinical trials without considerable certainty.

Arnold thought of this, and thought about what Yang Rui was doing now, he couldn't help pulling Fan Lundin aside, and said in a low voice: "You can think of a way to let Yang Rui quickly advance the research progress and expand the research scale, can it be done?"

"Why?" Valentine wondered.

"Don't worry about the reason, just do as I say." Arnold thought about it, and laughed to himself.

His main purpose of coming to China was to acquire the catalyst formula of coenzyme q10, and the two-month delay was almost his limit.

However, Yang Rui didn't seem to be affected by the time delay, which made Arnold not only frustrated, but also worried.

In his view, the main reason for this problem is that Yang Rui does not have an urgent need for funds.

At present, Yang Rui’s biggest expense is the lawyer’s fee, nearly one million U.S. dollars per month, which fully proves the seriousness and child’s play of American law, but Zeneca’s dividends of several million U.S. dollars every quarter fall on Yang Rui In hand, it is enough to solve the problem of attorney fees.

In this way, Yang Rui naturally did not have the urge to urgently sell the catalyst patent.

However, if Yang Rui invested too much in researching new drugs, things would be completely different.

Arnold is not completely sure how many shares Yang Rui has in Huarui, but through various understandings, Arnold is sure that Yang Rui has shares. The lawyer who helped Yang Rui set up the company back then was related to Zeneca. Although Arnold could not ask specific details, there was always general information.

Van Lundin didn't understand Arnold's purpose, so he could only say from the perspective of research: "When researching new drugs, everyone will carefully control the progress and scale of the research..."

"Yang Rui has never done research on new drugs before. If you give him suggestions, he might implement them."

"You want to send me to Huarui Laboratory as a guide?"

"Well, help them advance the progress of the experiment, speed it up a bit..." The initial cost of new drug research is not high, but the later cost is a bottomless pit.

Valentin did not think it was of any use, but obliged anyway.

The next day, when Van Lundin arrived at Huarui's laboratory, he realized that he seemed to be really wrong.

The research progress of Huarui Laboratory is much faster than he imagined.

...